164 related articles for article (PubMed ID: 25116754)
1. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.
Paulson KG; Tegeder A; Willmes C; Iyer JG; Afanasiev OK; Schrama D; Koba S; Thibodeau R; Nagase K; Simonson WT; Seo A; Koelle DM; Madeleine M; Bhatia S; Nakajima H; Sano S; Hardwick JS; Disis ML; Cleary MA; Becker JC; Nghiem P
Cancer Immunol Res; 2014 Nov; 2(11):1071-9. PubMed ID: 25116754
[TBL] [Abstract][Full Text] [Related]
2. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
3. Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity.
Ollier J; Kervarrec T; Samimi M; Benlalam H; Aumont P; Vivien R; Touzé A; Labarrière N; Vié H; Clémenceau B
Cancer Immunol Immunother; 2018 Aug; 67(8):1209-1219. PubMed ID: 29808366
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of Zeste Homolog 2 Inhibition Induces HLA Class I Re-Expression in Merkel Cell Carcinoma.
Durand MA; Drouin A; Bachiri K; Durand L; Berthon P; Houben R; Schrama D; Coyaud E; Samimi M; Touzé A; Kervarrec T
J Invest Dermatol; 2024 Jun; 144(6):1398-1401.e1. PubMed ID: 38052265
[No Abstract] [Full Text] [Related]
5. Biomaterial-Mediated Genetic Reprogramming of Merkel Cell Carcinoma and Melanoma Leads to Targeted Cancer Cell Killing
Luly KM; Green JJ; Sunshine JC; Tzeng SY
ACS Biomater Sci Eng; 2023 Nov; 9(11):6438-6450. PubMed ID: 37797944
[TBL] [Abstract][Full Text] [Related]
6. Targeting the epigenetic addiction of Merkel cell carcinoma.
Mauri F; Blanpain C
EMBO Mol Med; 2020 Nov; 12(11):e13347. PubMed ID: 33063436
[TBL] [Abstract][Full Text] [Related]
7. Rejection versus escape: the tumor MHC dilemma.
Garrido F; Ruiz-Cabello F; Aptsiauri N
Cancer Immunol Immunother; 2017 Feb; 66(2):259-271. PubMed ID: 28040849
[TBL] [Abstract][Full Text] [Related]
8. Single-Molecule RNA Sequencing Reveals IFNγ-Induced Differential Expression of Immune Escape Genes in Merkel Cell Polyomavirus-Positive MCC Cell Lines.
Sauerer T; Lischer C; Weich A; Berking C; Vera J; Dörrie J
Front Microbiol; 2021; 12():785662. PubMed ID: 35003017
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal multi-functional analysis identified responses of T cells, B cells, and monocytes as hallmarks of immunotherapy tolerance in patients with merkel cell carcinoma.
Tao Q; Du JX; Zhang S; Lin W; Luo Y; Liu Y; Zeng J; Chen XL
PLoS One; 2023; 18(11):e0293922. PubMed ID: 37983224
[TBL] [Abstract][Full Text] [Related]
10. Strategies to overcome low MHC-I expression in paediatric and adult tumours.
Guillaume J; Perzolli A; Boes M
Immunother Adv; 2024; 4(1):ltad028. PubMed ID: 38223409
[TBL] [Abstract][Full Text] [Related]
11. A Cell-Surface MHC-I Inhibitory Axis Promotes Immune Evasion in Cancer.
Cancer Discov; 2023 Oct; 13(10):2120. PubMed ID: 37594242
[TBL] [Abstract][Full Text] [Related]
12. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study.
Paulson KG; Iyer JG; Simonson WT; Blom A; Thibodeau RM; Schmidt M; Pietromonaco S; Sokil M; Warton EM; Asgari MM; Nghiem P
Am J Clin Pathol; 2014 Oct; 142(4):452-8. PubMed ID: 25239411
[TBL] [Abstract][Full Text] [Related]
13. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
14. Merkel Cell Carcinoma: Intersection of Immune Dysfunction, Infection, and Malignant Progression.
Nghiem P
J Investig Dermatol Symp Proc; 2015 Jul; 17(1):36. PubMed ID: 26067317
[No Abstract] [Full Text] [Related]
15. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma.
Ritter C; Fan K; Paulson KG; Nghiem P; Schrama D; Becker JC
Sci Rep; 2016 Feb; 6():21678. PubMed ID: 26902929
[TBL] [Abstract][Full Text] [Related]
16. Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival.
Vandeven N; Lewis CW; Makarov V; Riaz N; Paulson KG; Hippe D; Bestick A; Doumani R; Marx T; Takagishi S; Chan TA; Choi J; Nghiem P
Clin Cancer Res; 2018 Feb; 24(4):963-971. PubMed ID: 29246939
[No Abstract] [Full Text] [Related]
17. Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.
Miller NJ; Church CD; Dong L; Crispin D; Fitzgibbon MP; Lachance K; Jing L; Shinohara M; Gavvovidis I; Willimsky G; McIntosh M; Blankenstein T; Koelle DM; Nghiem P
Cancer Immunol Res; 2017 Feb; 5(2):137-147. PubMed ID: 28093446
[TBL] [Abstract][Full Text] [Related]
18. Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection.
Liu W; Yang R; Payne AS; Schowalter RM; Spurgeon ME; Lambert PF; Xu X; Buck CB; You J
Cell Host Microbe; 2016 Jun; 19(6):775-87. PubMed ID: 27212661
[TBL] [Abstract][Full Text] [Related]
19. Characterization of functional domains in the Merkel cell polyoma virus Large T antigen.
Houben R; Angermeyer S; Haferkamp S; Aue A; Goebeler M; Schrama D; Hesbacher S
Int J Cancer; 2015 Mar; 136(5):E290-300. PubMed ID: 25208506
[TBL] [Abstract][Full Text] [Related]
20. Merkel Cell Carcinoma Therapeutic Update.
Cassler NM; Merrill D; Bichakjian CK; Brownell I
Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
